Oxford Genetics, a provider of synthetic biology-based technologies for biologics discovery, development and delivery, has opened its first U.S. office located at the NGIN workplace near Kendall Square in the Cambridge district of Boston, MA.

By expanding into the U.S. market, the company says it is well positioned to respond to its existing customers’ needs, while also leveraging the very attractive sector and growing market.

This is the company’s first office outside of the UK, and will support its rapidly growing business in the U.S. and reinforce its commitment to delivering solutions that improve the discovery and development of biotherapeutics. Oxford Genetics aims to grow its U.S. commercial team to approximately 10 over the next 18 months, build on collaborative partnerships and will focus on driving sales, as well as strengthening its customer and technical support offering.

This global expansion follows the company’s latest successful round of financing in which it secured a £7.5 million investment that will also support the company’s 6,000-square foot expansion of its UK facility at Oxford Science Park. This will include state-of-the-art cell line engineering capabilities, viral vector production and purification suites, high-throughput robotic screening systems and process development facilities.

“Over the past twelve months we have seen increasing demand for our technologies and services from the U.S. market so the decision to expand our presence there was a logical step in the growth strategy of our business,” said Paul Brooks, chief commercial officer, Oxford Genetics. “The Boston area is a thriving hub for biotechnology talent and technologies which we look forward to being a part of, as well as increasing our ability to service a key growing market for Oxford Genetics.”